Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept (ACE-011) for the Treatment of Pulmonary Arterial Hypertension

Next Previous
Trial Profile

A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept (ACE-011) for the Treatment of Pulmonary Arterial Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotatercept (Primary) ; Antihypertensives
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms SPECTRA
  • Sponsors Acceleron Pharma

Most Recent Events

  • 16 May 2025 According to an Merck Sharp and Dohme media release, company announced data from this trial on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Societys (ATS) 2025 International Conference in San Francisco from May 16-21.
  • 01 May 2024 Primary endpoint (Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks) has been met as per results presented in Heart Failure.
  • 01 May 2024 Results of SPECTRA Phase 2b Study presented in the Circulation: Heart Failure

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top